Eagle Pharmaceuticals, Inc. (EGRX) Receives Consensus Rating of “Hold” from Brokerages

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has been given a consensus recommendation of “Hold” by the six ratings firms that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $62.33.

A number of analysts recently commented on EGRX shares. ValuEngine cut shares of Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Mizuho lowered their target price on shares of Eagle Pharmaceuticals from $40.00 to $37.00 and set an “underperform” rating for the company in a research note on Wednesday, September 6th. Piper Jaffray Companies reiterated a “buy” rating and issued a $75.00 target price on shares of Eagle Pharmaceuticals in a research note on Friday, October 27th. Royal Bank of Canada reiterated an “outperform” rating and issued a $75.00 target price (down from $81.00) on shares of Eagle Pharmaceuticals in a research note on Thursday, November 9th. Finally, BidaskClub upgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, December 2nd.

Eagle Pharmaceuticals (NASDAQ EGRX) traded up $1.08 during trading hours on Friday, hitting $54.78. 212,800 shares of the stock were exchanged, compared to its average volume of 336,658. Eagle Pharmaceuticals has a twelve month low of $45.05 and a twelve month high of $97.15. The company has a market cap of $790.85, a PE ratio of 8.47 and a beta of 1.24. The company has a quick ratio of 5.15, a current ratio of 5.30 and a debt-to-equity ratio of 0.26.

Several large investors have recently bought and sold shares of the company. Kopp Investment Advisors LLC increased its holdings in shares of Eagle Pharmaceuticals by 0.3% during the 2nd quarter. Kopp Investment Advisors LLC now owns 3,060 shares of the specialty pharmaceutical company’s stock valued at $241,000 after purchasing an additional 10 shares in the last quarter. Alps Advisors Inc. increased its holdings in shares of Eagle Pharmaceuticals by 0.3% during the 2nd quarter. Alps Advisors Inc. now owns 5,985 shares of the specialty pharmaceutical company’s stock valued at $472,000 after purchasing an additional 16 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Eagle Pharmaceuticals by 0.7% during the 2nd quarter. PNC Financial Services Group Inc. now owns 11,269 shares of the specialty pharmaceutical company’s stock valued at $889,000 after purchasing an additional 82 shares in the last quarter. D.A. Davidson & CO. increased its holdings in shares of Eagle Pharmaceuticals by 2.4% during the 2nd quarter. D.A. Davidson & CO. now owns 4,350 shares of the specialty pharmaceutical company’s stock valued at $343,000 after purchasing an additional 100 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan increased its holdings in shares of Eagle Pharmaceuticals by 6.7% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 1,910 shares of the specialty pharmaceutical company’s stock valued at $151,000 after purchasing an additional 120 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: “Eagle Pharmaceuticals, Inc. (EGRX) Receives Consensus Rating of “Hold” from Brokerages” was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.com-unik.info/2017/12/22/eagle-pharmaceuticals-inc-egrx-receives-consensus-rating-of-hold-from-brokerages.html.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit